Satralizumab monotherapy achieved a 55% reduction in the risk for relapses compared with placebo in patients with neuromyelitis optica spectrum disorder, according to a press release from Genentech.
The phase 3 multicenter, randomized, double-masked, placebo-controlled SAkuraStar study evaluated 95 patients with neuromyelitis optica spectrum disorder (NMOSD) between the ages of 20 and 70 years who were randomly assigned 2:1 to receive subcutaneous satralizumab 120 mg or placebo.
Of those treated with satralizumab, 76.1% were relapse-free at 48 weeks, with 72.1% being relapse-free at 96 weeks,
Uncategorized